📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Signal Management Plan (OBX-319)

Document ID: SIGNAL-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): GVP IX

Signal Management Plan — OBX-319

Process for detecting, validating, prioritising, assessing, and acting on safety signals for OBX-319 across clinical and post-marketing sources, feeding the RMP and the reference safety information. Immunogenicity considerations: Anti-drug antibody (binding and neutralising) assessment is integral; immunogenicity may affect exposure and is characterised with a tiered validated assay strategy.

Scope and objectives

This plan governs signal management for OBX-319, a humanized IgG1 anti-CD19 × anti-CD20 B-cell-depleting bispecific monoclonal antibody administered subcutaneously for moderate-to-severe active Systemic Lupus Erythematosus (SLE). It defines the routine and targeted activities by which the sponsor, Virtual Biopharma Inc., detects, validates, prioritises, assesses, and acts upon safety signals throughout the product lifecycle. The objective is to maintain a current and accurate characterisation of the product's safety profile, to ensure that new or changed risks are identified and evaluated promptly, and to feed conclusions into the Risk Management Plan (RMP) safety specification and pharmacovigilance plan and into the reference safety information (Investigator's Brochure during development; USPI, SmPC, and Company Core Data Sheet post-approval). The plan is prospective and living; the topics, thresholds, and methods are reviewed at least annually and whenever a material change to the safety profile occurs. Consistent with the modality, conventional small-molecule signal concerns that are not mechanistically plausible for a large protein therapeutic — QT/proarrhythmia liability, genotoxic or DNA-reactive metabolite formation, and cytochrome P450-mediated drug–drug interactions — are not allocated dedicated resources, and no boxed warning applies to the class.

Product and mechanistic context relevant to signal management

OBX-319 produces dual, near-complete depletion of circulating CD19+/CD20+ B lymphocytes. In the pivotal study OBX319-301 (Phase 3, randomized, double-blind, placebo-controlled, 1:1:1, 52 weeks, on background standard-of-care; N randomized 480 — 162 OBX-319 High, 158 OBX-319 Low, 160 Placebo), circulating CD19+ B cells fell from approximately 210 to approximately 7 cells/µL on the active arms and were unchanged on placebo, accompanied by declining anti-dsDNA titres and normalisation of complement C3/C4 in responders. The depth and duration of B-cell depletion define the mechanistic frame within which safety signals are interpreted: profound and sustained depletion is the direct driver of the class's important identified risks (serious and opportunistic infections; hypogammaglobulinaemia and secondary humoral immunodeficiency), and delayed B-cell reconstitution and immunoglobulin trajectories act as effect modifiers when infection-related events are assessed. Because there is no rodent cross-reactivity, the cynomolgus monkey is the sole pharmacologically relevant nonclinical species, and nonclinical infection/immunophenotyping findings from that species inform the a priori list of topics of interest. The molecule is subject to target-mediated drug disposition (TMDD), so pharmacokinetic variability — including that arising from immunogenicity — is a recognised modifier of exposure and, potentially, of the depth and duration of the pharmacodynamic effect.

Roles and responsibilities

Signal management is executed within the sponsor's pharmacovigilance system under the accountability of the EU Qualified Person for Pharmacovigilance (QPPV), with an equivalent responsible safety officer for the US operation. Day-to-day detection and medical review are performed by the Pharmacovigilance/Drug Safety function under a designated safety physician. A cross-functional Signal Management Team (safety physician, PV scientist, epidemiologist/quantitative safety scientist, clinical, regulatory, and, as required, clinical pharmacology and biostatistics) conducts validation and assessment. A periodic Safety Review Board provides governance oversight, endorses validated signals and their prioritisation, and ratifies recommended actions. Roles, decision authority, escalation paths, and record-keeping are documented in the pharmacovigilance system master file and supporting standard operating procedures.

Data sources

Signal detection draws on all data available to the sponsor:

Source	Contribution to signal detection
Clinical trial safety database (OBX319-301; N randomized 480) and any subsequent/open-label extension studies	Comparative active-vs-placebo review; aggregate blinded and, per the DSMB charter, unblinded review of adverse events, laboratory (immunoglobulins, B-cell counts), and pharmacodynamic data
Spontaneous individual case safety reports (ICSRs)	Post-approval reports via FDA FAERS (21 CFR 600.80) and EudraVigilance; qualitative and, when volume permits, quantitative screening
Signal detection systems	EudraVigilance/EVDAS electronic reaction monitoring reports and statistical disproportionality (PRR, ROR, EBGM/MGPS) once sufficient post-marketing data accrue
Scientific and medical literature	Systematic periodic screening, including class-wide safety findings for B-cell-depleting biologics
Immunogenicity dataset	Anti-drug antibody incidence, titre, and neutralising-antibody status from the tiered validated assay strategy
Aggregate reports and external inputs	DSUR (ICH E2F) and PBRER (ICH E2C(R2)); registries, patient support and market-research programmes, licensing-partner exchanges, and regulatory-authority communications

Signal detection methodology

During the development and early post-approval period, when exposure numbers are limited, detection is predominantly qualitative medical review supplemented by triggered, targeted analyses of the pre-specified topics of interest. Active-versus-placebo comparisons in OBX319-301 are examined for excess or dose-ordering across the OBX-319 High (162), OBX-319 Low (158), and Placebo (160) arms, and MedDRA Standardised MedDRA Queries (SMQs) are run for serious/opportunistic infection, hypersensitivity, hypogammaglobulinaemia and immunodeficiency, demyelination/progressive multifocal leukoencephalopathy, and malignancy. As post-marketing data accumulate, routine statistical signal detection (disproportionality with predefined thresholds and time-trend monitoring) is applied in EVDAS and FAERS, with special attention to designated medical events, while qualitative review of serious and unlisted reports continues irrespective of statistical output. Detection of immunogenicity-related signals additionally tracks the temporal association between rising anti-drug antibody titre or neutralising-antibody positivity and either loss of the expected pharmacodynamic effect (B-cell repopulation, rising anti-dsDNA) or administration/hypersensitivity events.

Signal validation

Each detected observation is validated to determine whether the available evidence supports a new potential causal association, or a new aspect of a known association, warranting further evaluation. Validation examines the strength and consistency of the evidence, biological plausibility in the context of dual B-cell depletion, the number and quality of cases, temporal relationship, dechallenge/rechallenge information, and whether the event is already reflected in the reference safety information. The rationale for validating, or not validating, is documented. Serious, medically important, and designated medical events are reviewed on an ongoing (continuous) basis rather than only at periodic intervals.

Signal prioritisation

Validated signals are prioritised so that those with the greatest potential impact on patients or public health are addressed first. Prioritisation weighs the seriousness, reversibility, and outcome of the reaction; the strength and novelty of the evidence; the size of the exposed population; designated-medical-event status; and the potential for preventive action. For OBX-319, signals touching serious or opportunistic infection, hypogammaglobulinaemia/secondary immunodeficiency, hypersensitivity/anaphylaxis, and any suggestion of progressive multifocal leukoencephalopathy receive the highest priority given the mechanism.

Signal assessment

Prioritised signals undergo structured assessment integrating all relevant data — clinical-trial and spontaneous cases, literature, class experience, pharmacodynamic and immunogenicity findings, and, where informative, exposure–response and TMDD-based pharmacokinetic considerations. The assessment concludes whether a causal relationship is supported, whether the reference safety information adequately describes the risk, and what further action, if any, is required. Assessments are documented to a standard suitable for regulatory review and are reflected, as appropriate, in the next DSUR or PBRER.

Recommendation, decision-making, and actions

Assessment outcomes are brought to the Safety Review Board, which endorses one or more actions: no action beyond continued routine surveillance; update of the reference safety information (USPI/SmPC/CCDS/IB); update of the RMP safety specification, pharmacovigilance plan, or risk-minimisation measures; initiation of additional pharmacovigilance activities (for example, targeted follow-up questionnaires, a post-authorisation safety study, or enhanced monitoring); direct healthcare-professional communication; or notification to regulatory authorities. Where a signal constitutes an emerging safety issue that may materially affect the benefit–risk balance, it is escalated and notified to competent authorities within the required timelines rather than deferred to the next periodic report.

Product-specific safety topics under active surveillance

The following topics are maintained under targeted surveillance from first-in-human exposure and are searched at every signal-detection cycle:

Topic	Classification	Mechanistic basis / monitoring approach
Serious and opportunistic infections (including viral reactivation, tuberculosis, sepsis, Pneumocystis)	Important identified risk	Direct consequence of B-cell depletion; SMQ-based case review, active-vs-placebo rate comparison, biomarker context from B-cell reconstitution
Hypogammaglobulinaemia and secondary humoral immunodeficiency	Important identified risk	Sustained depletion may lower serum immunoglobulins; laboratory (IgG/IgM) trend review and association with infection reporting
Progressive multifocal leukoencephalopathy	Important potential risk	Recognised concern for profound/prolonged B-cell depletion; heightened index of suspicion and targeted follow-up of any suggestive neurological report
Administration and hypersensitivity reactions (injection-site reactions; systemic hypersensitivity including anaphylaxis)	Identified risk	Expected for a subcutaneous therapeutic protein; consistent with the injection-site reaction events observed in OBX319-301
Immunogenicity / anti-drug antibodies	Identified risk / effect modifier	Binding and neutralising antibody assessment; potential impact on exposure (TMDD), pharmacodynamics, and hypersensitivity
Impaired response to vaccination	Potential risk	Reduced humoral response during depletion; monitored via literature and targeted follow-up
Malignancy	Potential risk	Theoretical consequence of chronic immunomodulation; long-term routine monitoring
Reproductive and developmental effects	Potential risk	B-cell depletion in offspring (enhanced pre/postnatal development findings in cynomolgus monkey); pregnancy and lactation exposure surveillance

Immunogenicity signal management

Immunogenicity is managed as an integral, cross-cutting component of signal detection. The tiered validated assay strategy — screening, confirmatory, titre, and neutralising-antibody characterisation — generates the data used to monitor anti-drug antibody incidence and persistence. Signals are sought in three directions: an impact on exposure (accelerated clearance mediated by anti-drug antibodies superimposed on target-mediated drug disposition), an impact on pharmacodynamics and efficacy (premature B-cell reconstitution or attenuated depletion accompanied by rising anti-dsDNA), and an impact on safety (association of neutralising or high-titre responses with hypersensitivity and administration reactions). Findings are reconciled with the pharmacokinetic and immunogenicity sections of the clinical documentation and feed the reference safety information.

Pharmacodynamic and biomarker context for signal interpretation

The pharmacodynamic markers characterised in OBX319-301 — near-complete CD19+ B-cell depletion (approximately 210 to approximately 7 cells/µL on active arms versus unchanged placebo), falling anti-dsDNA, and normalising complement C3/C4 — are used not as efficacy endpoints in this plan but as interpretive context for safety signals. The depth and durability of depletion frame the plausibility and expected magnitude of infection and hypogammaglobulinaemia signals, and the timing of B-cell reconstitution and immunoglobulin recovery informs the assessment of temporally associated infection events. This biomarker framing supports mechanistically coherent causality assessment rather than reliance on reporting frequency alone.

Interfaces with the RMP, reference safety information, and aggregate reports

Conclusions from signal management are the primary input to lifecycle risk documentation. Validated and assessed signals update the RMP safety specification and, where warranted, the pharmacovigilance plan and risk-minimisation measures; they are reflected in the reference safety information (IB during development; USPI, SmPC, and CCDS after approval); and they are summarised, with their evaluation and outcome, in the DSUR (ICH E2F) and PBRER (ICH E2C(R2)). This ensures a single, consistent characterisation of the product's evolving benefit–risk profile across the submission.

Tracking, documentation, and governance review cadence

All validated signals are recorded in a signal tracking log capturing the source, date of detection, validation and prioritisation rationale, assessment status, decision, action taken, and closure. The status of open signals is reviewed at each Safety Review Board meeting; the plan itself, including the list of topics of interest and the detection thresholds and methods, is reviewed at least annually and upon any material change to the safety profile or exposure. Records are maintained to a standard suitable for regulatory inspection and are traceable to the corresponding entries in the periodic aggregate reports.

GVP Module IX; supported by ICH E2E, ICH E2C(R2), and ICH E2F, with post-marketing safety reporting under 21 CFR 600.80.